JoVE Logo

Anmelden

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces the same desired effect at a lower dose. It is noteworthy that both drugs exhibit similar maximum effect or Emax values, implying that they possess equal efficacy. Efficacy depends on the number of drug–receptor complexes formed and the extent of receptor activation. Maximal efficacy is achieved when all receptors are occupied, rendering further increases in drug concentration incapable of eliciting additional responses. Full agonists have high efficacy, as they activate receptors entirely and elicit a complete response. The efficacy of partial agonists is lower, as they activate receptors to a lesser extent. Antagonists, in contrast, exhibit zero efficacy by not activating the receptors. Instead, they act as blockers and either reduce the number of available receptors for agonist binding or induce conformational changes that prevent effective agonist binding. Overall, these factors play a crucial role in determining the efficacy and potency of drugs, which, in turn, can determine their usefulness in treating various medical conditions.

Tags

Dose response RelationshipPotencyEfficacyEC50 ValuesCandesartanIrbesartanMaximum EffectEmax ValuesDrug receptor ComplexesReceptor ActivationFull AgonistsPartial AgonistsAntagonistsDrug ConcentrationMedical Treatment

Aus Kapitel 4:

article

Now Playing

4.9 : Dose-Response Relationship: Potency and Efficacy

Pharmacodynamics

4.0K Ansichten

article

4.1 : Prinzipien der Arzneimittelwirkung

Pharmacodynamics

5.6K Ansichten

article

4.2 : Ziele für die Wirkung von Medikamenten: Überblick

Pharmacodynamics

5.9K Ansichten

article

4.3 : Signaltransduktion: Übersicht

Pharmacodynamics

8.1K Ansichten

article

4.4 : Wandlermechanismus: G-Protein-gekoppelte Rezeptoren

Pharmacodynamics

1.7K Ansichten

article

4.5 : Ligandengesteuerter Ionenkanalrezeptor: Gating-Mechanismus

Pharmacodynamics

2.0K Ansichten

article

4.6 : Wandlermechanismus: Enzymgebundene Rezeptoren

Pharmacodynamics

2.3K Ansichten

article

4.7 : Wandlermechanismus: Kernrezeptoren

Pharmacodynamics

1.2K Ansichten

article

4.8 : Dosis-Wirkungs-Beziehung: Überblick

Pharmacodynamics

2.8K Ansichten

article

4.10 : Dosis-Wirkungs-Beziehung: Selektivität und Spezifität

Pharmacodynamics

6.2K Ansichten

article

4.11 : Therapeutischer Index

Pharmacodynamics

4.0K Ansichten

article

4.12 : Arzneimittel-Rezeptor-Interaktion: Agonist

Pharmacodynamics

2.3K Ansichten

article

4.13 : Arzneimittel-Rezeptor-Interaktion: Antagonist

Pharmacodynamics

2.5K Ansichten

article

4.14 : Kombinierte Wirkungen von Medikamenten: Antagonismus

Pharmacodynamics

8.1K Ansichten

article

4.15 : Kombinierte Wirkungen von Medikamenten: Synergismus

Pharmacodynamics

3.6K Ansichten

See More

JoVE Logo

Datenschutz

Nutzungsbedingungen

Richtlinien

Forschung

Lehre

ÜBER JoVE

Copyright © 2025 MyJoVE Corporation. Alle Rechte vorbehalten